A Phase 2 interventional study of Esketamine 14 mg and Esketamine 28 mg in Treatment Resistant Depressive Disorder, sponsored by Janssen Research & Development, LLC. Completed at 25 sites in 3 countries. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.
Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 13th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 2nd registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, China, Japan and 1 more country
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
The George Institute · Sites in Australia
Ages 18+
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 210 across the 18 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson: 1 open now, 1 under way, 1 of them phase 3. Of 18 finished, 11 (61%) have results posted.
Among the 21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 2, and was the 4th registered.
Johnson & Johnson’s Depressive Disorder, Treatment-Resistant studies by the year they started, since 2010.
1 of the studies testing esketamine in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06278779The George InstituteComparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 21 in Depressive Disorder, Treatment-Resistant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants with treatment-resistant depression (TRD).
This will be a 2-panel, randomized ( participants are assigned different treatments based on chance), double-blind (neither investigator nor participant knows which treatment the participant receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), multicenter study. Approximately 100 male and female adult participants diagnosed with TRD will participate in this study. For participants in both panels (Panel A and Panel B), there will be 4 study phases: a 4-week screening phase, a double-blind treatment phase (Day 1 to Day 15), an optional open-label treatment phase (Panel A: Day 15 to 74; Panel B: Day 15 to 25), and an 8-week post-treatment (follow-up) phase. Depending on the treatment Panel, patients will be assigned to intranasal placebo or intranasal esketamine 14 mg, 28 mg, 56 mg, or 84 mg. Safety assessments will be performed throughout the study. The maximum study duration for a participant will be 23 weeks for Panel A and 16 weeks for Panel B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
--Participant must meet -Fourth Edition -Text Revised (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder (MDD), without psychotic features, based upon clinical assessment, and confirmed by the Mini International Neuropsychiatric Interview (MINI)-Participant's major depressive episode and treatment response must be deemed "valid" by remote independent raters-Participant must have had an inadequate response to at least 2 antidepressants, at least one of which is in the current episode of depression; the antidepressant treatment response questionnaire (ATRQ) will be used to assess antidepressant treatment response during the current episode; prior medication history will be used to determine antidepressant treatment response in prior episode(s) -Have an Inventory of Depressive Symptoms-Clinician rated, 30-item (IDS-C30) total score >=34 at Screening and predose at Day 1
Exclusion Criteria:
-Participant has a current diagnosis of bipolar and related disorders, intellectual disability, or cluster b personality disorder (e.g., borderline personality disorder, antisocial personality disorder, histrionic personality disorder, and narcissistic personality disorder) -Participant has a current or prior DSM-IV-TR diagnosis of a psychotic disorder, MDD with psychosis, post-traumatic stress disorder (PTSD), or obsessive compulsive disorder (OCD) -Anatomical or medical conditions that may impede delivery or absorption of study medication (e.g., undergone facial reconstruction, rhinoplasty, significant structural or functional abnormalities of the nose or upper airway; obstructions or mucosal lesions of the nostrils or nasal passages; undergone sinus surgery in the previous 2 years; signs and symptoms of rhinitis) -Has an abnormal or deviated nasal septum with any 1 or more of the following symptoms: blockage of 1 or both nostrils, nasal congestion (especially 1-sided), frequent nosebleeds, frequent sinus infections, and at times has facial pain, headaches, and postnasal drip -Has a history of substance abuse (drug or alcohol) or dependence (except nicotine or caffeine) within the previous 1 year of the screening visit -Participant has known allergies, , intolerance, or to esketamine/ketamine or its
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
Drug: Esketamine 14 mg · Drug: Esketamine 56 mg · Drug: Placebo
Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
Drug: Esketamine 28 mg · Drug: Esketamine 56 mg · Drug: Placebo
Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
Drug: Esketamine 56 mg · Drug: Placebo
Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
Drug: Esketamine 56 mg · Drug: Esketamine 84 mg · Drug: Placebo
Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
Drug: Esketamine 14 mg · Drug: Esketamine 28 mg · Drug: Esketamine 56 mg · Drug: Esketamine 84 mg · Drug: Placebo
1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.
Time frame: Baseline (Day 1) and Endpoint (Day 8) of Period 1
Panel A and B: Change From Baseline (Day 8) in Montgomery Asberg Depression Rating Scale Total Score at Day 15- ANCOVA Analysis
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.
Time frame: Baseline (Day 8) and Endpoint (Day 15) of Period 2
Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Have Completed the Double-Blind Phase and Received the Same Treatment for Both Periods
Sustained response was defined as at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Day 2 Up to Day 15
Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Received the Same Treatment for Both Periods, Including Participants Who Did Not Complete the Double-blind Phase
Sustained response was defined as at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Day 2 Up to Day 15
Panel A and B: Percentage of Participants With Response Based on MADRS Total Score
A participant is defined a responder at a given time point if the percent improvement in MADRS is greater than or equal to (\>=) 50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Period 1: Days 1 (2 hour), 2 and 8 of Double-blind Phase
Panel A and B: Percentage of Participants With Response Based on MADRS Total Score
A participant is defined a responder at a given time point if the percent improvement in MADRS is \>=50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Period 2: Days 1 (2 hour), 2 and 8 of Double-blind Phase
Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase
Participants who had a MADRS total score of \<=10 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
Time frame: Days 1, 2 and 8 of Double-blind Phase of Period 1
Panel A and B: Percentage of Participants in Remission Based on MADRS Total Score at Days 1, 2 and 8 of Double-blind Phase
Participants who had a MADRS total score of less than or equal to (\<=10) were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.
Time frame: Days 1, 2 and 8 of Double-blind Phase of Period 2
Panel A and B: Change From Baseline (Day 1) in Quick Inventory of Depressive Symptomatology-16-item Self Report (QIDS-SR16) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.
Time frame: Baseline (Day 1) and Endpoint (Day 8) of Period 1
Panel A and B: Change From Baseline (Day 8) in Quick Inventory of Depressive Symptomatology-16-item Self Report Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.
Time frame: Baseline (Day 8) and Endpoint (Day 15) of Period 2
Panel A and B: Change From Baseline (Day 1) in Clinical Global Impression - Severity (CGI-S) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.
Time frame: Baseline (Day 1) and Endpoint (Day 8) of Period 1
Panel A and B: Change From Baseline (Day 8) in Clinical Global Impression - Severity Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.
Time frame: Baseline (Day 8) and Endpoint (Day 15) of Period 2
Panel A and B: Change From Baseline (Day 1) in Generalized Anxiety Disorder (GAD-7) Total Score at Day 8 (Double-Blind Treatment Phase) ANCOVA Analysis
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).
Time frame: Baseline (Day 1) and Endpoint (Day 8) of Period 1
Panel A and B: Change From Baseline (Day 8) in Generalized Anxiety Disorder-7 Total Score at Day 15 (Double-Blind Treatment Phase)- ANCOVA Analysis
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).
Time frame: Baseline (Day 8) and Endpoint (Day 15) of Period 2
Panel A and B: Change From Baseline (Day 1) in Patient Global Impression of Severity (PGI-S) Score Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition.
Time frame: Baseline (Day 1) and Endpoint (Day 8) of Period 1
Panel A and B: Change From Baseline (Day 8) in Patient Global Impression of Severity Score Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. A negative change in score indicates improvement.
Time frame: Baseline (Day 8) and Endpoint (Day 15) of Period 2
| Milestone | Placebo (Panel A: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Esketamine 56 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Placebo (Panel B: Period 1) | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel B: Period 1) | Placebo (Panel A: Period 2) QIDS >= 11 Participants | Placebo (Panel A: Period 2) QIDS<11 Participants | Placebo to Esketamine 28mg (Panel A: Period 2) | Placebo to Esketamine 56 mg (Panel A: Period 2) | Placebo to Esketamine 84 mg (Panel A: Period 2) | Esketamine 28 mg (Panel A: Period 2) | Esketamine 56 mg (Panel A: Period 2) | Esketamine 84 mg (Panel A: Period 2) | Placebo (Panel B: Period 2) QIDS >=11 Participants | Placebo (Panel B: Period 2) QIDS<11 Participants | Placebo to Esketamine 14mg (Panel B: Period 2) | Placebo to Esketamine 56mg (Panel B: Period 2) | Esketamine 14 mg (Panel B: Period 2) | Esketamine 56 mg (Panel B: Period 2) | Placebo/Placebo/Open Label Esketamine (Panel A) | Placebo/Esketamine/Open Label Esketamine (Panel A) | Esketamine/Esketamine/Open Label Esketamine (Panel A) | Placebo/Placebo/Open Label Esketamine (Panel B) | Placebo/Esketamine/Open Label Esketamine (Panel B) | Esketamine/Esketamine/Open Label Esketamine (Panel B) | Placebo: Follow up Phase | Esketamine 14 mg: Follow up Phase | Esketamine 28 mg: Follow up Phase | Esketamine 56 mg: Follow up Phase | Esketamine 84 mg: Follow up Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 33 | 11 | 11 | 12 | 21 | 11 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rerandomized to esketamine 56 mg | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rerandomized to esketamine 28mg | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rerandomized to esketamine 84mg | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 32 | 8 | 11 | 12 | 21 | 11 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (Panel A: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Esketamine 56 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Placebo (Panel B: Period 1) | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel B: Period 1) | Placebo (Panel A: Period 2) QIDS >= 11 Participants | Placebo (Panel A: Period 2) QIDS<11 Participants | Placebo to Esketamine 28mg (Panel A: Period 2) | Placebo to Esketamine 56 mg (Panel A: Period 2) | Placebo to Esketamine 84 mg (Panel A: Period 2) | Esketamine 28 mg (Panel A: Period 2) | Esketamine 56 mg (Panel A: Period 2) | Esketamine 84 mg (Panel A: Period 2) | Placebo (Panel B: Period 2) QIDS >=11 Participants | Placebo (Panel B: Period 2) QIDS<11 Participants | Placebo to Esketamine 14mg (Panel B: Period 2) | Placebo to Esketamine 56mg (Panel B: Period 2) | Esketamine 14 mg (Panel B: Period 2) | Esketamine 56 mg (Panel B: Period 2) | Placebo/Placebo/Open Label Esketamine (Panel A) | Placebo/Esketamine/Open Label Esketamine (Panel A) | Esketamine/Esketamine/Open Label Esketamine (Panel A) | Placebo/Placebo/Open Label Esketamine (Panel B) | Placebo/Esketamine/Open Label Esketamine (Panel B) | Esketamine/Esketamine/Open Label Esketamine (Panel B) | Placebo: Follow up Phase | Esketamine 14 mg: Follow up Phase | Esketamine 28 mg: Follow up Phase | Esketamine 56 mg: Follow up Phase | Esketamine 84 mg: Follow up Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 8 | 9 | 5 | 8 | 11 | 12 | 5 | 8 | 5 | 3 | 11 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 8 | 8 | 5 | 8 | 11 | 10 | 5 | 8 | 5 | 2 | 11 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (Panel A: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Esketamine 56 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Placebo (Panel B: Period 1) | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel B: Period 1) | Placebo (Panel A: Period 2) QIDS >= 11 Participants | Placebo (Panel A: Period 2) QIDS<11 Participants | Placebo to Esketamine 28mg (Panel A: Period 2) | Placebo to Esketamine 56 mg (Panel A: Period 2) | Placebo to Esketamine 84 mg (Panel A: Period 2) | Esketamine 28 mg (Panel A: Period 2) | Esketamine 56 mg (Panel A: Period 2) | Esketamine 84 mg (Panel A: Period 2) | Placebo (Panel B: Period 2) QIDS >=11 Participants | Placebo (Panel B: Period 2) QIDS<11 Participants | Placebo to Esketamine 14mg (Panel B: Period 2) | Placebo to Esketamine 56mg (Panel B: Period 2) | Esketamine 14 mg (Panel B: Period 2) | Esketamine 56 mg (Panel B: Period 2) | Placebo/Placebo/Open Label Esketamine (Panel A) | Placebo/Esketamine/Open Label Esketamine (Panel A) | Esketamine/Esketamine/Open Label Esketamine (Panel A) | Placebo/Placebo/Open Label Esketamine (Panel B) | Placebo/Esketamine/Open Label Esketamine (Panel B) | Esketamine/Esketamine/Open Label Esketamine (Panel B) | Placebo: Follow up Phase | Esketamine 14 mg: Follow up Phase | Esketamine 28 mg: Follow up Phase | Esketamine 56 mg: Follow up Phase | Esketamine 84 mg: Follow up Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 20 | 27 | 13 | 7 | 19 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 11 | 23 | 13 | 7 | 19 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 9 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (Panel A: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Esketamine 56 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Placebo (Panel B: Period 1) | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel B: Period 1) | Placebo (Panel A: Period 2) QIDS >= 11 Participants | Placebo (Panel A: Period 2) QIDS<11 Participants | Placebo to Esketamine 28mg (Panel A: Period 2) | Placebo to Esketamine 56 mg (Panel A: Period 2) | Placebo to Esketamine 84 mg (Panel A: Period 2) | Esketamine 28 mg (Panel A: Period 2) | Esketamine 56 mg (Panel A: Period 2) | Esketamine 84 mg (Panel A: Period 2) | Placebo (Panel B: Period 2) QIDS >=11 Participants | Placebo (Panel B: Period 2) QIDS<11 Participants | Placebo to Esketamine 14mg (Panel B: Period 2) | Placebo to Esketamine 56mg (Panel B: Period 2) | Esketamine 14 mg (Panel B: Period 2) | Esketamine 56 mg (Panel B: Period 2) | Placebo/Placebo/Open Label Esketamine (Panel A) | Placebo/Esketamine/Open Label Esketamine (Panel A) | Esketamine/Esketamine/Open Label Esketamine (Panel A) | Placebo/Placebo/Open Label Esketamine (Panel B) | Placebo/Esketamine/Open Label Esketamine (Panel B) | Esketamine/Esketamine/Open Label Esketamine (Panel B) | Placebo: Follow up Phase | Esketamine 14 mg: Follow up Phase | Esketamine 28 mg: Follow up Phase | Esketamine 56 mg: Follow up Phase | Esketamine 84 mg: Follow up Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 12 | 39 | 42 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 12 | 39 | 42 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.
| Unit on a scale | Panel A: Period 1 Placebo | Panel A: Period 1 Esketamine 28 mg | Panel A: Period 1 Esketamine 56 mg | Panel A: Period 1 Esketamine 84 mg | Panel B: Period 1 Placebo | Panel B: Period 1 Esketamine 14 mg | Panel B: Period 1 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis | -4.9 ± 1.74 | -9.8 ± 2.72 | -12.4 ± 2.66 | -15.3 ± 2.56 | -6.6 ± 1.53 | -4.8 ± 2.13 | -10.3 ± 2.36 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.
| Unit on a scale | Panel A: Period 2 Placebo | Panel A:Period 2 Esketamine 28 mg | Panel A: Period 2 Esketamine 56 mg | Panel A: Period 2 Esketamine 84 mg | Panel B: Period 2 Placebo | Panel B: Period 2 Esketamine 14 mg | Panel B:Period 2 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 8) in Montgomery Asberg Depression Rating Scale Total Score at Day 15- ANCOVA Analysis | -4.5 ± 2.92 | -7.6 ± 2.49 | -8.9 ± 2.51 | -11.4 ± 2.68 | -0.7 ± 3.32 | -6.6 ± 4.02 | -1.2 ± 6.04 |
Sustained response was defined as at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Panel A: Placebo (Period 1 and 2) | Panel A: Esketamine 28 mg (Period 1 and 2) | Panel A: Esketamine 56 mg (Period 1 and 2) | Panel A: Esketamine 84 mg (Period 1 and 2) | Panel B: Placebo (Period 1 and 2) | Panel B: Esketamine 14 mg (Period 1 and 2) | Panel B: Esketamine 56 mg (Period 1 and 2) |
|---|---|---|---|---|---|---|---|
| Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Have Completed the Double-Blind Phase and Received the Same Treatment for Both Periods | 0 | 12.5 | 9.1 | 30.0 | 15.4 | 18.2 | 22.2 |
Sustained response was defined as at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 that is maintained to study Day 15. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Panel A: Placebo (Period 1 and 2) | Panel A: Esketamine 28 mg (Period 1 and 2) | Panel A: Esketamine 56 mg (Period 1 and 2) | Panel A: Esketamine 84 mg (Period 1 and 2) | Panel B: Placebo (Period 1 and 2) | Panel B: Esketamine 14 mg (Period 1 and 2) | Panel B: Esketamine 56 mg (Period 1 and 2) |
|---|---|---|---|---|---|---|---|
| Panel A and B: Percentage of Participants With Sustained Response Based on MADRS Total Score in Participants Who Received the Same Treatment for Both Periods, Including Participants Who Did Not Complete the Double-blind Phase | 0 | 12.5 | 9.1 | 25.0 | 15.4 | 18.2 | 22.2 |
A participant is defined a responder at a given time point if the percent improvement in MADRS is greater than or equal to (\>=) 50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Panel A: Period 1 Placebo | Panel A: Period 1 Esketamine 28 mg | Panel A: Period 1 Esketamine 56 mg | Panel A: Period 1 Esketamine 84 mg | Panel B: Period 1 Placebo | Panel B: Period 1 Esketamine 14 mg | Panel B: Period 1 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Day 1 (2 hour) | 18.2 | 54.5 | 36.4 | 58.3 | 33.3 | 36.4 | 44.4 |
| Day 2 | 3.0 | 36.4 | 27.3 | 41.7 | 28.6 | 36.4 | 44.4 |
| Day 8 | 6.1 | 9.1 | 18.2 | 41.7 | 23.8 | 18.2 | 22.2 |
A participant is defined a responder at a given time point if the percent improvement in MADRS is \>=50%. Participant who do not meet such criterion, worsen or discontinue during the DB phase for any reason was considered as non-responders, that is, was assigned a value of 0. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Panel A: Period 2 Placebo | Panel A: Period 2 Esketamine 28 mg | Panel A: Period 2 Esketamine 56 mg | Panel A: Period 2 Esketamine 84 mg | Panel B: Period 2 Placebo | Panel B: Period 2 Esketamine 14 mg | Panel B: Period 2 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Day 1 (2 hour) | 16.7 | 12.5 | 22.2 | 40.0 | 0 | 60.0 | 0 |
| Day 2 | 0 | 0 | 11.1 | 40.0 | 0 | 80.0 | 0 |
| Day 8 | 0 | 12.5 | 0 | 20.0 | 0 | 0 | 33.3 |
Participants who had a MADRS total score of \<=10 were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.
| Percentage of participants | Panel A: Period 1: Placebo | Panel A: Period 1 Esketamine 28 mg | Panel A: Period 1: Esketamine 56 mg | Panel A: Period 1 Esketamine 84 mg | Panel B: Period 1 Placebo | Panel B: Period 1 Esketamine 14 mg | Panel B: Period 1 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Day 1 | 3.0 | 27.3 | 18.2 | 25.0 | 19.0 | 36.4 | 33.3 |
| Day 2 | 0 | 36.4 | 18.2 | 25.0 | 19.0 | 27.3 | 33.3 |
| Day 8 | 3.0 | 9.1 | 9.1 | 25.0 | 14.3 | 18.2 | 22.2 |
Participants who had a MADRS total score of less than or equal to (\<=10) were considered remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. A negative change in score indicates improvement.
| Percentage of participants | Panel A: Period 2 Placebo | Panel A: Period 2 Esketamine 28 mg | Panel A: Period 2 Esketamine 56 mg | Panel A: Period 2 Esketamine 84 mg | Panel B: Period 2 Placebo | Panel B: Period 2 Esketamine 14 mg | Panel B: Period 2 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Day 1 | 16.7 | 12.5 | 0 | 40.0 | 0 | 60.0 | 0 |
| Day 2 | 0 | 0 | 0 | 20.0 | 0 | 80.0 | 0 |
| Day 8 | 0 | 12.5 | 0 | 20.0 | 0 | 0 | 0 |
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.
| Unit on a scale | Panel A: Period 1 Placebo | Panel A: Period 1 Esketamine 28 mg | Panel A: Period 1 Esketamine 56 mg | Panel A: Period 1 Esketamine 84 mg | Panel B: Period 1 Placebo | Panel B: Period 1 Esketamine 14 mg | Panel B: Period 1 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 1) in Quick Inventory of Depressive Symptomatology-16-item Self Report (QIDS-SR16) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis | -1.8 ± 0.93 | -4.0 ± 1.43 | -4.4 ± 1.43 | -4.2 ± 1.39 | -1.1 ± 0.78 | -0.6 ± 1.10 | -3.0 ± 1.20 |
QIDS-SR16 is self-rated scale assesses severity of depressive symptoms. Total scores range from 0-27. Higher score indicates greater severity of depression. Negative change in score indicates improvement. Total score obtained by adding scores for each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders-4th edition major depressive disorder (DSM-IV MDD) criteria: depressed mood, loss of interest/pleasure, concentration/decision making, self-outlook, suicidal ideation, energy/fatigability, sleep, weight/appetite change, psychomotor changes. 16 items used to rate 9 criterion domains: 4 items used to rate sleep disturbance (early/middle/late insomnia/hypersomnia); 2 items used to rate psychomotor disturbance (agitation, retardation); 4 items used to rate appetite/weight disturbance. 1 item used to rate 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, suicidal ideation). Each item was rated 0-3.
| Unit on a scale | Panel A: Period 2 Placebo | Panel A: Period 2 Esketamine 28 mg | Panel A: Period 2 Esketamine 56 mg | Panel A: Period 2 Esketamine 84 mg | Panel B: Period 2 Placebo | Panel B: Period 2 Esketamine 14 mg | Panel B: Period 2 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 8) in Quick Inventory of Depressive Symptomatology-16-item Self Report Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis | -2.0 ± 1.50 | -3.1 ± 1.35 | -2.0 ± 1.41 | -3.3 ± 1.48 | -2.1 ± 1.78 | -5.7 ± 1.78 | -1.5 ± 2.31 |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.
| Units on a scale | Panel A: Period 1 Placebo | Panel A: Period 1 Esketamine 28 mg | Panel A: Period 1 Esketamine 56 mg | Panel A: Period 1 Esketamine 84 mg | Panel B: Period 1 Placebo | Panel B: Period 1 Esketamine 14 mg | Panel B: Period 1 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 1) in Clinical Global Impression - Severity (CGI-S) Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks | 5.0 (1 to 6) | 4.0 (3 to 5) | 4.0 (1 to 5) | 4.0 (1 to 6) | 4.0 (1 to 6) | 4.0 (2 to 6) | 3.0 (3 to 6) |
CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. A negative change in score indicates improvement.
| Units on a scale | Panel A: Period 2 Placebo | Panel A: Period 2 Esketamine 28 mg | Panel A: Period 2 Esketamine 56 mg | Panel A: Period 2 Esketamine 84 mg | Panel B: Period 2 Placebo | Panel B: Period 2 Esketamine 14 mg | Panel B: Period 2 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 8) in Clinical Global Impression - Severity Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks | 5.0 (4 to 5) | 4.0 (3 to 5) | 5.0 (4 to 6) | 4.0 (3 to 5) | 4.0 (3 to 6) | 3.0 (3 to 4) | 4.0 (4 to 5) |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).
| Unit on a scale | Panel A: Period 1 Placebo | Panel A: Period 1 Esketamine 28 mg | Panel A: Period 1 Esketamine 56 mg | Panel A: Period 1 Esketamine 84 mg | Panel B: Period 1 Placebo | Panel B: Period 1 Esketamine 14 mg | Panel B: Period 1 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 1) in Generalized Anxiety Disorder (GAD-7) Total Score at Day 8 (Double-Blind Treatment Phase) ANCOVA Analysis | -1.7 ± 0.88 | -1.5 ± 1.34 | -3.1 ± 1.34 | -5.1 ± 1.30 | -1.7 ± 0.68 | -1.9 ± 0.94 | -3.2 ± 1.03 |
GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).
| Unit on a scale | Panel A: Period 2 Placebo | Panel A: Period 2 Esketamine 28 mg | Panel A: Period 2 Esketamine 56 mg | Panel A: Period 2 Esketamine 84 mg | Panel B: Period 2 Placebo | Panel B: Period 2 Esketamine 14 mg | Panel B: Period 2 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 8) in Generalized Anxiety Disorder-7 Total Score at Day 15 (Double-Blind Treatment Phase)- ANCOVA Analysis | 0.4 ± 1.02 | -1.6 ± 0.87 | 1.0 ± 0.98 | -0.9 ± 1.02 | -2.7 ± 1.68 | -6.6 ± 1.68 | -0.7 ± 2.27 |
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition.
| Unit on a scale | Panel A: Period 1 Placebo | Panel A: Period 1 Esketamine 28 mg | Panel A: Period 1 Esketamine 56 mg | Panel A: Period 1 Esketamine 84 mg | Panel B: Period 1 Placebo | Panel B: Period 1 Esketamine 14 mg | Panel B: Period 1 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 1) in Patient Global Impression of Severity (PGI-S) Score Total Score at Day 8 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks | 3.0 (2 to 4) | 3.0 (1 to 4) | 3.0 (1 to 3) | 3.0 (1 to 4) | 3.0 (2 to 4) | 3.0 (1 to 3) | 3.0 (2 to 3) |
PGI-S is a patient-rated scale that assesses the severity of their illness at the time of assessment, relative to participants past experience. It is a 4-point (1 to 4) scale in response to the question 'Considering all aspects of your depression right now would you say your depression is?' with scores as follows: 1: none; 2: mild; 3: moderate; 4: severe. A higher score implies a more severe condition. A negative change in score indicates improvement.
| Unit on a scale | Panel A: Period 2 Placebo | Panel A: Period 2 Esketamine 28 mg | Panel A: Period 2 Esketamine 56 mg | Panel A: Period 2 Esketamine 84 mg | Panel B: Period 2 Placebo | Panel B: Period 2 Esketamine 14 mg | Panel B: Period 2 Esketamine 56 mg |
|---|---|---|---|---|---|---|---|
| Panel A and B: Change From Baseline (Day 8) in Patient Global Impression of Severity Score Total Score at Day 15 in the Double-Blind Treatment Phase- ANCOVA Analysis on Ranks | 3.0 (2 to 4) | 3.0 (2 to 4) | 4.0 (2 to 4) | 3.0 (2 to 4) | 3.0 (2 to 3) | 3.0 (2 to 3) | 3.0 (2 to 4) |
Collected over Up to 21 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Panel A and B: Period 1) | — | 0/54 (0%) | 27/54 (50%) |
| Esketamine 28 mg (Panel A: Period 1) | — | 0/11 (0%) | 8/11 (72.7%) |
| Placebo (Panel A and B: Period 2) QIDS >=11 Participants | — | 1/23 (4.3%) | 15/23 (65.2%) |
| Placebo to Esketamine 14mg (Panel B: Period 2) | — | 0/5 (0%) | 5/5 (100%) |
| Placebo to Esketamine 28mg (Panel A: Period 2) | — | 0/8 (0%) | 4/8 (50%) |
| Placebo to Esketamine 56mg (Panel A and B: Period 2) | — | 0/12 (0%) | 11/12 (91.7%) |
| Placebo to Esketamine 84 mg (Panel A: Period 2) | — | 0/5 (0%) | 5/5 (100%) |
| Placebo (Panel A and Panel B: Period 2) | — | 1/23 (4.3%) | 12/23 (52.2%) |
| Esketamine 14 mg (Panel B: Period 2) | — | 0/16 (0%) | 11/16 (68.8%) |
| Esketamine 28 mg (Panel A: Period 2) | — | 0/16 (0%) | 8/16 (50%) |
| Esketamine 56 mg (Panel A and B: Period 2) | — | 0/32 (0%) | 26/32 (81.3%) |
| Placebo/Placebo/Open Label Esketamine (Panel A and B) | — | 0/23 (0%) | 23/23 (100%) |
| Placebo/Esketamine/Open Label Esketamine (Panel A and B) | — | 0/27 (0%) | 22/27 (81.5%) |
| Esketamine/Esketamine/Open Label Esketamine (Panel A and B) | — | 1/46 (2.2%) | 39/46 (84.8%) |
| Placebo: Follow up Phase | — | 0/1 (0%) | 0/1 (0%) |
| Esketamine 14 mg: Follow up Phase | — | 0/4 (0%) | 1/4 (25%) |
| Esketamine 28 mg: Follow up Phase | — | 1/12 (8.3%) | 4/12 (33.3%) |
| Esketamine 56 mg: Follow up Phase | — | 1/39 (2.6%) | 10/39 (25.6%) |
| Esketamine 84 mg: Follow up Phase | — | 1/42 (2.4%) | 7/42 (16.7%) |
| Esketamine 14 mg (Panel B: Period 1) | — | 0/11 (0%) | 6/11 (54.5%) |
| Esketamine 56 mg (Panel A and B: Period 1) | — | 0/20 (0%) | 18/20 (90%) |
| Esketamine 84 mg (Panel A: Period 1) | — | 0/12 (0%) | 10/12 (83.3%) |
| Esketamine 84 mg (Panel A: Period 2) | — | 0/17 (0%) | 12/17 (70.6%) |
| Event | Placebo (Panel A and B: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Placebo (Panel A and B: Period 2) QIDS >=11 Participants | Placebo to Esketamine 14mg (Panel B: Period 2) | Placebo to Esketamine 28mg (Panel A: Period 2) | Placebo to Esketamine 56mg (Panel A and B: Period 2) | Placebo to Esketamine 84 mg (Panel A: Period 2) | Placebo (Panel A and Panel B: Period 2) | Esketamine 14 mg (Panel B: Period 2) | Esketamine 28 mg (Panel A: Period 2) | Esketamine 56 mg (Panel A and B: Period 2) | Placebo/Placebo/Open Label Esketamine (Panel A and B) | Placebo/Esketamine/Open Label Esketamine (Panel A and B) | Esketamine/Esketamine/Open Label Esketamine (Panel A and B) | Placebo: Follow up Phase | Esketamine 14 mg: Follow up Phase | Esketamine 28 mg: Follow up Phase | Esketamine 56 mg: Follow up Phase | Esketamine 84 mg: Follow up Phase | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel A and B: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Confusional StatePsychiatric disorders | 0/1 | 0/3 | 0/23 | 0/5 | 0/8 | 0/12 | 0/5 | 0/11 | 0/8 | 0/16 | 0/12 | 0/23 | 0/27 | 0/46 | 0/1 | 0/4 | 1/12 | 0/39 | 0/42 | — | — | — | — |
| OesophagitisGastrointestinal disorders | 0/54 | 0/11 | 1/23 | 0/5 | 0/8 | 0/12 | 0/5 | 1/23 | 0/16 | 0/16 | 0/32 | 0/23 | 0/27 | 0/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 0/11 | 0/20 | 0/12 | 0/17 |
| Completed SuicidePsychiatric disorders | 0/1 | 0/3 | 0/23 | 0/5 | 0/8 | 0/12 | 0/5 | 0/11 | 0/8 | 0/16 | 0/12 | 0/23 | 0/27 | 0/46 | 0/1 | 0/4 | 0/12 | 1/39 | 0/42 | — | — | — | — |
| General Physical Health DeteriorationGeneral disorders | 0/1 | 0/3 | 0/23 | 0/5 | 0/8 | 0/12 | 0/5 | 0/11 | 0/8 | 0/16 | 0/12 | 0/23 | 0/27 | 0/46 | 0/1 | 0/4 | 0/12 | 0/39 | 1/42 | — | — | — | — |
| Ectopic PregnancyPregnancy, puerperium and perinatal conditions | 0/1 | 0/3 | 0/23 | 0/5 | 0/8 | 0/12 | 0/5 | 0/11 | 0/8 | 0/16 | 0/12 | 0/23 | 0/27 | 1/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | — | — | — | — |
| Event | Placebo (Panel A and B: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Placebo (Panel A and B: Period 2) QIDS >=11 Participants | Placebo to Esketamine 14mg (Panel B: Period 2) | Placebo to Esketamine 28mg (Panel A: Period 2) | Placebo to Esketamine 56mg (Panel A and B: Period 2) | Placebo to Esketamine 84 mg (Panel A: Period 2) | Placebo (Panel A and Panel B: Period 2) | Esketamine 14 mg (Panel B: Period 2) | Esketamine 28 mg (Panel A: Period 2) | Esketamine 56 mg (Panel A and B: Period 2) | Placebo/Placebo/Open Label Esketamine (Panel A and B) | Placebo/Esketamine/Open Label Esketamine (Panel A and B) | Esketamine/Esketamine/Open Label Esketamine (Panel A and B) | Placebo: Follow up Phase | Esketamine 14 mg: Follow up Phase | Esketamine 28 mg: Follow up Phase | Esketamine 56 mg: Follow up Phase | Esketamine 84 mg: Follow up Phase | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel A and B: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 1/54 | 4/11 | 0/23 | 2/5 | 0/8 | 4/12 | 3/5 | 0/23 | 2/16 | 2/16 | 11/32 | 7/23 | 9/27 | 14/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 1/11 | 7/20 | 5/12 | 5/17 |
| DysgeusiaNervous system disorders | 9/54 | 2/11 | 6/23 | 1/5 | 1/8 | 2/12 | 3/5 | 4/23 | 2/16 | 1/16 | 4/32 | 4/23 | 6/27 | 9/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 1/11 | 4/20 | 3/12 | 4/17 |
| NauseaGastrointestinal disorders | 5/54 | 2/11 | 3/23 | 1/5 | 0/8 | 2/12 | 2/5 | 2/23 | 1/16 | 1/16 | 3/32 | 4/23 | 6/27 | 6/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 1/11 | 5/20 | 2/12 | 2/17 |
| Feeling AbnormalGeneral disorders | 1/54 | 2/11 | 1/23 | 2/5 | 0/8 | 0/12 | 0/5 | 1/23 | 4/16 | 0/16 | 3/32 | 4/23 | 4/27 | 7/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 2/11 | 4/20 | 1/12 | 1/17 |
| HeadacheNervous system disorders | 4/54 | 4/11 | 5/23 | 0/5 | 2/8 | 3/12 | 1/5 | 4/23 | 1/16 | 2/16 | 3/32 | 4/23 | 5/27 | 5/46 | 0/1 | 1/4 | 0/12 | 0/39 | 4/42 | 2/11 | 4/20 | 2/12 | 1/17 |
| DissociationPsychiatric disorders | 1/54 | 0/11 | 0/23 | 1/5 | 0/8 | 4/12 | 1/5 | 0/23 | 1/16 | 0/16 | 8/32 | 2/23 | 4/27 | 8/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 0/11 | 6/20 | 3/12 | 2/17 |
| SomnolenceNervous system disorders | 3/54 | 1/11 | 7/23 | 1/5 | 0/8 | 2/12 | 0/5 | 6/23 | 1/16 | 1/16 | 5/32 | 7/23 | 5/27 | 5/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 2/11 | 2/20 | 0/12 | 0/17 |
| Dissociative DisorderPsychiatric disorders | 0/54 | 1/11 | 0/23 | 0/5 | 1/8 | 0/12 | 1/5 | 0/23 | 0/16 | 1/16 | 1/32 | 4/23 | 2/27 | 3/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 0/11 | 1/20 | 3/12 | 3/17 |
| InsomniaPsychiatric disorders | 1/54 | 0/11 | 1/23 | 0/5 | 0/8 | 2/12 | 0/5 | 0/23 | 0/16 | 0/16 | 2/32 | 0/23 | 0/27 | 0/46 | 0/1 | 1/4 | 1/12 | 1/39 | 0/42 | 0/11 | 0/20 | 0/12 | 0/17 |
| HypertensionVascular disorders | 2/54 | 0/11 | 0/23 | 0/5 | 0/8 | 3/12 | 0/5 | 0/23 | 1/16 | 0/16 | 3/32 | 0/23 | 1/27 | 2/46 | 0/1 | 0/4 | 0/12 | 0/39 | 0/42 | 0/11 | 1/20 | 1/12 | 1/17 |
| Age, Continuous(years) | Placebo (Panel A: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Esketamine 56 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Placebo (Panel B: Period 1) | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel B: Period 1) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 44.4 ± 9.60 | 42.1 ± 10.31 | 42.7 ± 11.23 | 49.8 ± 9.29 | 45.3 ± 7.66 | 42.2 ± 9.43 | 45.6 ± 7.35 | 44.6 ± 9.29 |
| Sex: Female, Male(Participants) | Placebo (Panel A: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Esketamine 56 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Placebo (Panel B: Period 1) | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel B: Period 1) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 18 | 5 | 9 | 6 | 9 | 4 | 4 | 55 |
| Male | 15 | 6 | 2 | 6 | 12 | 7 | 5 | 53 |
| Race (NIH/OMB)(Participants) | Placebo (Panel A: Period 1) | Esketamine 28 mg (Panel A: Period 1) | Esketamine 56 mg (Panel A: Period 1) | Esketamine 84 mg (Panel A: Period 1) | Placebo (Panel B: Period 1) | Esketamine 14 mg (Panel B: Period 1) | Esketamine 56 mg (Panel B: Period 1) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 21 | 11 | 9 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 4 | 4 | 1 | 0 | 0 | 0 | 18 |
| White | 24 | 7 | 6 | 11 | 0 | 0 | 0 | 48 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Jan 2014 to primary completion in Jul 2015, 17 months.
Results were first posted in Jun 2019, 3 years 10 months after primary completion. A results delay was requested in Apr 2016.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Depressive Disorder, Treatment-Resistant →
Janssen Research & Development, LLC →